-+ 0.00%
-+ 0.00%
-+ 0.00%

VIKING THERAPEUTICS PRESENTS DATA FROM ITS 13-WEEK PHASE 2 VENTURE-ORAL DOSING TRIAL OF VK2735 AT EUROPEAN CONGRESS ON OBESITY (ECO) 2026

Reuters·05/12/2026 11:05:00

Please log in to view news